Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects

Status Suspended

Clinical Trial Summary

In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection. In this study, we aim to evaluate the virological and clinical outcomes of subjects following a contact at high/moderate risk of SARS-CoV-2 acquisition, in community-subjects and/or healthcare workers. The study population is represented by all subjects who had a contact with laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at high/moderate risk of SARS-CoV-2 acquisition. This include both children and adult subjects, subject without social security, and healthcare workers.

Clinical Trial Description

Procedures added by the research: Blood sampling for determination of the presence of SARS-CoV-2 type M immunoglobulins or type G immunoglobulins. Blood sampling for whole exome sequencing ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04322279
Study type	Observational
Source	Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status	Suspended
Phase
Start date	March 9, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05065827` - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting	`NCT05359770` - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19	N/A
Completed	`NCT04515147` - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19	Phase 2
Not yet recruiting	`NCT06025812` - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)	N/A
Recruiting	`NCT05289115` - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS	N/A
Completed	`NCT04953078` - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19	Phase 1
Completed	`NCT04779138` - Increasing Vaccine Uptake in Underresourced Public Housing Areas	N/A
Not yet recruiting	`NCT05868239` - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study	N/A
Completed	`NCT04690413` - NOWDx Test for the Detection of Antibodies to COVID-19	N/A
Completed	`NCT04818164` - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04572399` - UVA Light Device to Treat COVID-19	N/A
Recruiting	`NCT04610567` - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)	Phase 1/Phase 2
Recruiting	`NCT04772170` - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting	`NCT04581954` - Inflammatory Signal Inhibitors for COVID-19 (MATIS)	Phase 1/Phase 2
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Completed	`NCT05572840` - Wear Your Mask, Wash Your Hands, Don't Get COVID-19	N/A
Withdrawn	`NCT04838847` - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19	Phase 3
Completed	`NCT04556149` - imPulse™ Una Full-spectrum, Over Clothing E-stethoscope

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms